Xeris Biopharma Holdings, Inc. (XERS) Q1 2024 Earnings
XERS·Reported May 9, 2024·Before market open
Xeris Biopharma Holdings, Inc. reported Q1 2024 revenue of $40.6M, missed analyst consensus of $41.8M by $1.2M. Diluted EPS came in at $-0.14, missed the $-0.12 consensus by $0.02.
Revenue
$40.6Mmissed by $1.2M
Consensus: $41.8MDiluted EPS
$-0.14missed by $0.02
Consensus: $-0.12
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Xeris Biopharma Holdings, Inc.'s Q1 2024 earnings report.
Xeris Biopharma Holdings, Inc. (XERS) reported Q1 2024 earnings on May 9, 2024 before market open.
Xeris Biopharma Holdings, Inc. reported revenue of $40.6M and diluted EPS of $-0.14 for Q1 2024.
Revenue missed the consensus estimate of $41.8M by $1.2M. EPS missed the consensus estimate of $-0.12 by $0.02.
You can read the 10-Q periodic report (0001867096-24-000065) directly on SEC EDGAR. The filing index links above go to sec.gov.